Compare Eli Lilly And Co (LLY) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Remitly Global Inc — how do they compare? Eli Lilly And Co trades at $1,176.52 (market cap $1.04T), while Remitly Global Inc trades at $23.81 (market cap $4.98B). The key difference: Eli Lilly And Co is far larger — about 208.8× Remitly Global Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Remitly Global Inc for 53 Days on average.
| LLY | RELY | |
|---|---|---|
Market Cap | $1.04T | $4.98B |
Volume | 3,064,878 | 3,501,150 |
Sector | Health | Technology |
52-Week High | $1.28K | $26.92 |
52-Week Low | $799.57 | $12.20 |
Typical Hold Time | 93 Days | 53 Days |
Enterprise Value | $1.09T | $4.34B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
RELY trades at $23.675, up 3.25% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats. Revenue surged to $1.64 billion in 2025, with net income turning positive at $67.93 million, reflecting a significant improvement in profitability. Recent news highlights partnerships, such as with Etsy, and strong analyst consensus favoring the stock.
The outlook for RELY is positive, driven by robust revenue growth, expanding margins, and a favorable analyst consensus with a $30.50 price target. Key risks include competitive pressures in fintech and reliance on sustained customer acquisition, but institutional interest and insider holdings suggest confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
